Search
Yipinhong: Clinical Trial Registration Application for Subsidiary's Innovative Drug APH03621 Tablet Approved
2025-08-04 /
Read about 0 minute
Author：小编
Yipinhong has announced that the National Medical Products Administration has accepted the clinical trial application for APH03621 tablet, an innovative drug developed by its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical. The company has received the official "Notice of Acceptance." APH03621, which has not been introduced domestically or internationally, falls under Class 1 of chemical drug registration and is designed to treat endometriosis.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
